524661 WELCURE

Welcure Drugs & Pharmaceuticals Share Price

₹7.28 -0.28 (-3.7%)

23 Feb, 2025 03:52

SIP TrendupStart SIP in WELCURE

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -24.32%
  • Over 3 Month -9.79%
  • Over 6 Month -0.68%
  • Over 1 Year + 54.89%
SIP Lightning

Smart Investing Starts Here Start SIP with Welcure Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Welcure Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Welcure Drugs & Pharmaceuticals Financials

Welcure Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹7.28
-0.28 (-3.7%)
pointer
  • stock-down_img
  • Bearish Moving Average 15
  • stock-up_img
  • Bullish Moving Average 1
  • 20 Day
  • ₹9.10
  • 50 Day
  • ₹9.48
  • 100 Day
  • ₹8.75
  • 200 Day
  • ₹7.43

Resistance and Support

7.45 Pivot Speed
  • R3 8.42
  • R2 8.15
  • R1 7.72
  • S1 7.02
  • S2 6.75
  • S3 6.32

What's your outlook on Welcure Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Welcure Drugs & Pharms. has an operating revenue of Rs. 33.52 Cr. on a trailing 12-month basis. An annual revenue de-growth of -63% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -12% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 13% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Welcure Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-11-14 Quarterly Results (Revised)
2024-10-21 Others
2024-08-14 Quarterly Results
2024-06-10 Others Inter alia, 1. To augment of financial resources of the company, 2. To increase in authorised share capital of the company and 3. To shift branch office of the company.

Welcure Drugs & Pharmaceuticals F&O

Welcure Drugs & Pharmaceuticals Shareholding Pattern

0%
98.79%
1.21%

About Welcure Drugs & Pharmaceuticals

  • NSE Symbol
  • WELCURE
  • BSE Symbol
  • 524661
  • Managing Director & CFO
  • Mr. Altaf Hussain Shah
  • ISIN
  • INE331C01017

Similar Stocks to Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals FAQs

Welcure Drugs & Pharmaceuticals share price is ₹7 As on 23 February, 2025 | 03:38

The Market Cap of Welcure Drugs & Pharmaceuticals is ₹81.9 Cr As on 23 February, 2025 | 03:38

The P/E ratio of Welcure Drugs & Pharmaceuticals is 43.4 As on 23 February, 2025 | 03:38

The PB ratio of Welcure Drugs & Pharmaceuticals is 0.8 As on 23 February, 2025 | 03:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23